Emerging invasive zygomycosis in a tertiary care center: Epidemiology and associated risk factors

International Journal of Infectious Diseases

Volumn 14, Issue SUPPL. 3, 2010, Pages

  Ambrosioni, Juan ^a   Bouchuiguir Wafa, Kalthum ^a   Garbino, Jorge ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Amphotericin B; Breakthrough infections; Fungal infections; Incidence; Posaconazole; Voriconazole; Zygomycosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; VORICONAZOLE;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; FEMALE; FUNGUS ISOLATION; HOSPITAL ADMISSION; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; MALE; NONHUMAN; RISK FACTOR; SWITZERLAND; TERTIARY HEALTH CARE; ZYGOMYCETES; ZYGOMYCOSIS;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; CHILD; COMMUNICABLE DISEASES, EMERGING; FEMALE; HEMATOLOGIC NEOPLASMS; HOSPITALS, TEACHING; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SWITZERLAND; TREATMENT OUTCOME; ZYGOMYCOSIS;

EID: 77957344559     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.11.024     Document Type: Article

References (24)

1. Pagano L., Caira M., Candoni A., Offidani M., Fianchi L., Martino B., et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006, 91:1068-1075.
2. Imhof A., Balajee S.A., Fredricks D.N., Englund J.A., Marr K.A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39:743-746.
3. Malani A.N., Kauffman C.A. Changing epidemiology of rare mold infections: implications for therapy. Drugs 2007, 67:1803-1812.
4. Trifilio S., Singhal S., Williams S., Frankfurt O., Gordon L., Evens A., et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007, 40:451-456.
5. Brown J. Zygomycosis: an emerging fungal infection. Am J Health Syst Pharm 2005, 62:2593-2596.
6. Chayakulkeeree M., Ghannoum M.A., Perfect J.R. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006, 25:215-229.
7. Ameen M., Arenas R., Martinez-Luna E., Reyes M., Zacarias R. The emergence of mucormycosis as an important opportunistic fungal infection: five cases presenting to a tertiary referral center for mycology. Int J Dermatol 2007, 46:380-384.
8. Ustun C., Farrow S., DeRemer D., Fain H., Jillella A.P. Early fatal Rhizopus infection on voriconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 2007, 39:807-808.
9. Trifilio S.M., Bennett C.L., Yarnold P.R., McKoy J.M., Parada J., Mehta J., et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007, 39:425-429.
10. Torres-Narbona M., Guinea J., Martínez-Alarcón J., Muñoz P., Peláez T., Bouza E. Workload and clinical significance of the isolation of zygomycetes in a tertiary general hospital. Med Mycol 2008, 46:225-230.
11. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., Chamilos G., Healy M., Perego C., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
12. Suzuki K., Sugawara Y., Sekine T., Nakase K., Katayama N. Breakthrough disseminated zygomycosis induced massive gastrointestinal bleeding in a patient with acute myeloid leukemia receiving micafungin. J Infect Chemother 2009, 15:42-45.
13. Girmenia C., Moleti M.L., Micozzi A., Iori A.P., Barberi W., Foà R., et al. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J Clin Microbiol 2005, 43:5395-5396.
14. Lamaris G.A., Ben-Ami R., Lewis R.E., Chamilos G., Samonis G., Kontoyiannis D.P. Increased virulence of zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 2009, 199:1399-1406.
15. Shpitzer T., Keller N., Wolf M., Goldschmied-Reouven A., Bahar G., Bahar I., et al. Seasonal variations in rhino-cerebral Mucor infection. Ann Otol Rhinol Laryngol 2005, 114:695-698.
16. Al-Ajam M.R., Bizri A.R., Mokhbat J., Weedon J., Lutwick L. Mucormycosis in the Eastern Mediterranean: a seasonal disease. Epidemiol Infect 2006, 134:341-346.
17. Rogers T.R. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 2008, 61(Suppl 1):i35-40.
18. Kauffman C.A., Malani A.N. Zygomycosis: an emerging fungal infection with new options for management. Curr Infect Dis Rep 2007, 9:435-440.
19. Peel T., Daffy J., Thursky K., Stanley P., Buising K. Posaconazole as first line treatment for disseminated zygomycosis. Mycoses 2008, 51:542-545.
20. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348-359.
21. Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356:335-347.
22. Gonzalez A.V., Ullmann A.J., Almyroudis N.G., Segal B.H. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point. J Natl Compr Canc Netw 2008, 6:175-182.
23. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007, 78:275-282.
24. Grigg M., Slavin M. Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy. Transpl Infect Dis 2008, 10:3-12.